Review
Pharmacology & Pharmacy
Young-A Heo
Summary: Budesonide/glycopyrronium/formoterol is an inhaled fixed-dose combination approved for the maintenance treatment of COPD, effectively reducing exacerbations and improving lung function in patients with inadequately controlled disease.
Article
Respiratory System
Maarten van den Berge, Jan De Backer, Cedric van Holsbeke, Wilfried De Backer, Roopa Trivedi, Martin Jenkins, Paul Dorinsky, Magnus Aurivillius
Summary: This study found that triple therapy with BGF resulted in greater improvements in lung function compared to dual therapy with GFF in patients with moderate-to-severe COPD, reflecting the contribution of the ICS component in reducing airway resistance and increasing airway volume.
RESPIRATORY RESEARCH
(2021)
Article
Respiratory System
Nethmi Kearns, Pepa Bruce, Mathew Williams, Marjan Doppen, Melissa Black, Mark Weatherall, Richard Beasley
Summary: Comparative bronchodilator effects of salbutamol and budesonide/formoterol in stable asthma patients showed differences in systemic beta(2)-agonist, cardiovascular effects, and adverse events.
EUROPEAN RESPIRATORY JOURNAL
(2022)
Article
Immunology
Mingming Deng, Yan Yin, Qin Zhang, Xiaoming Zhou, Gang Hou
Summary: This study aimed to identify effective biomarkers for COPD through differential expressed genes analysis and weighted co-expression network analysis. The results suggest that Lp-PLA2 may be a potential biomarker for assessing exercise tolerance in COPD patients.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Pharmacology & Pharmacy
Paraskevi Kyriaki Monou, Eleftherios G. Andriotis, Nikolaos Bouropoulos, Emmanuel Panteris, Melpomeni Akrivou, Ioannis S. Vizirianakis, Zeeshan Ahmad, Dimitrios G. Fatouros
Summary: In this study, a multi-component system for pulmonary delivery was developed, including engineered microparticles and investigation of two active pharmaceutical ingredients. All formulations exhibited satisfactory performance and drug release. Physicochemical properties evaluation showed appropriate morphology and aerodynamic performance of the microparticles, with release of the active ingredients monitored in simulated lung fluid.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
(2021)
Review
Nutrition & Dietetics
Angela Tramontano, Paolo Palange
Summary: Chronic Obstructive Pulmonary Disease (COPD) is a global epidemic causing numerous deaths annually. It is characterized by progressive and often irreversible airflow obstruction with varying clinical manifestations. Malnutrition is commonly observed in COPD patients and can worsen respiratory function and prognosis. Nutritional impairment is associated with reduced exercise tolerance and impact on patient-perceived quality of life. However, there is limited data on the best strategies to manage malnutrition in COPD patients. This review highlights the importance of COPD-related malnutrition on muscle function, exercise tolerance, and dyspnea.
Article
Cardiac & Cardiovascular Systems
Flavia Rossi Caruso, Cassia da Luz Goulart, Jose Carlos Bonjorno Jr, Claudio Ricardo de Oliveira, Renata Goncalves Mendes, Ross Arena, Audrey Borghi-Silva
Summary: Weber classification can be used to stratify cardiorespiratory fitness in COPD patients. Patients in Weber D group had lower exercise capacity and higher dyspnea compared to Weber A and B groups. Heart rate and forced expiratory volume in one second were significant predictors of peak oxygen consumption.
Article
Allergy
Helen Kathryn Reddel, Guy Brusselle, Rosa Lamarca, Per Gustafson, Gary P. Anderson, Carin Jorup
Summary: This study aimed to evaluate the safety and effectiveness of as needed formoterol in patients taking maintenance ICS-formoterol or ICS-salmeterol. The results showed that as-needed formoterol significantly reduced exacerbation risk in patients on maintenance ICS-formoterol but not in patients on maintenance ICS-salmeterol.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2023)
Review
Medicine, General & Internal
Richard Beasley, Tim Harrison, Stefan Peterson, Per Gustafson, Angus Hamblin, Thomas Bengtsson, Malin Fageras
Summary: This study found that switching to SMART treatment was associated with a longer time to the first severe asthma exacerbation for patients with poorly controlled asthma. Compared to escalating or continuing GINA treatment with inhaled corticosteroid-long-acting beta(2)-agonist plus short-acting beta(2)-agonist reliever, the SMART regimen was preferred.
Article
Respiratory System
David H. Au, Emily Gleason, Rachel Hunter-Merrill, Anna E. Baron, Margaret Collins, Corina Ronneberg, Nan Lv, Peter Rise, Travis Hee Wai, Robert Plumley, Stephen R. Wisniewski, Frank C. Sciurba, Dong-Yun Kim, Paul Simonelli, Jerry A. Krishnan, Christine H. Wendt, Laura C. Feemster, Gerard J. Criner, Veeranna Maddipati, Arjun Mohan, Jun Ma
Summary: Among overweight or obese patients with COPD, a self-guided low-intensity video-based lifestyle intervention led to modest weight loss but did not lead to clinically important improvements in physical functional status and dyspnea.
ANNALS OF THE AMERICAN THORACIC SOCIETY
(2023)
Article
Respiratory System
Shigeo Muro, Hisatoshi Sugiura, Patrick Darken, Paul Dorinsky
Summary: In the KRONOS study, triple therapy with BGF MDI was shown to significantly improve lung function and reduce exacerbation rates in patients with moderate-to-very severe COPD without airway reversibility and EOS < 300 cells/mm(3). This indicates that BGF can benefit a broad range of COPD patients, regardless of reversible airflow obstruction or high eosinophil counts.
RESPIRATORY RESEARCH
(2021)
Article
Critical Care Medicine
Paul M. O'Byrne, J. Mark FitzGerald, Eric D. Bateman, Peter J. Barnes, Jinping Zheng, Per Gustafson, Rosa Lamarca, Margareta Puu, Christina Keen, Vijay K. T. Alagappan, Helen K. Reddel
Summary: In patients with mild asthma, as-needed budesonide-formoterol reduces the short-term risk of severe exacerbations after a single day of higher use. The use of an anti-inflammatory reliever may reduce the risk of short-term severe exacerbations by providing increased doses of inhaled corticosteroids and formoterol when symptoms occur.
LANCET RESPIRATORY MEDICINE
(2021)
Article
Allergy
Helen K. Reddel, Paul M. O'Byrne, J. Mark FitzGerald, Peter J. Barnes, Jinping Zheng, Stefan Ivanov, Rosa Lamarca, Margareta Puu, Vijay K. T. Alagappan, Eric D. Bateman
Summary: This post hoc pooled analysis of SYGMA 1 and 2 showed that as-needed BUD-FORM was superior to maintenance BUD and similar to as-needed terbutaline in reducing severe exacerbations in adolescents with mild asthma. Adherence to maintenance treatment was higher in the BUD-FORM group compared to the BUD maintenance group, and no new safety concerns were identified.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2021)
Article
Respiratory System
Felipe V. C. Machado, Martijn A. Spruit, Miriam T. J. Groenen, Sarah Houben-Wilke, Paula P. van Melick, Nidia A. Hernandes, Annemie M. W. J. Schols, Fabio Pitta, Emiel F. M. Wouters, Frits M. E. Franssen
Summary: This study analyzed data from 469 COPD patients and found that over half of overweight and obese patients have low muscle mass when using age-gender-BMI-specific cut-offs. Low muscle mass is associated with worse functional outcomes in overweight and obese COPD patients.
RESPIRATORY RESEARCH
(2021)
Article
Respiratory System
Edward C. Portillo, Michael Pollack, Inyoung Lee, Kainan Sun, Xiaohui Zhao, Lisa Kruse, Norbert Feigler, Sushma Patel, Aimee M. Near
Summary: This study examines the use of BGF triple therapy in COPD patients and finds that it is being initiated in patients with symptoms and exacerbations, often accompanied by other cardiopulmonary comorbidities.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE
(2023)